Aortic valve replacement (AVR) is the mainstay of treatment of symptomatic severe aortic stenosis (AS) as it offers substantial improvements in symptoms and life expectancy.
The aortic valve surgery will entails substantially which risks for the patients with severe comorbidities, and also considered at “extreme” risk, surgery is not appropriate.
Percutaneous balloon aortic valvotomy (also known as balloon aortic valvuloplasty) was developed as a less invasive means to treat severe AS but has limited utility and substantial risks. Subsequently it was developed ,as transcatheter aortic valve implantation (TAVI) which is an alternative method for treating severe AS in selected patients with unacceptably high estimated surgical risks.
A multidisciplinary team approach is recommended in approaching patients with symptomatic AS and choosing between surgical AVR, TAVI, and medical therapy, with possible use of percutaneous balloon aortic valvotomy.